{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"7","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Patients will be enrolled prior to admission for High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT), and they will undergo their planned HDT-AHCT for their respective hematologic malignancy as per institutional standards.","id":"OG000","title":"Romiplostim"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"up to 100 days from AHCT","title":"Number of Platelet Transfusions Per Participant Issued During the AHCT Admission","type":"SECONDARY","unitOfMeasure":"number of platelet transfusions per pt"}